

ImCare - Model Seravue - Diagnostic Kit
ImCare Biotech is developing a diagnostic kit, Seravue®, for the early detection of liver cancer, which is supported by an SBIR phase II grant from the National Cancer Institute (NCI, NIH).
Seravue® is a liver cancer diagnostic kit that could help millions of people affected by Hepatocellular Carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) worldwide, and is based on the quantitative assessment of a specific protein which is secreted only in cases of liver cancer.
The technology has shown tremendous promise in preliminary studies and is currently undergoing intensive clinical testing. Compared to tests based on AFP (Alpha Fetoprotein), an existing biomarker for HCC, Seravue® has demonstrated superior accuracy and broader applicability.
Our IM-08 technology, with its high specificity and sensitivity, will be the foundation for a best-in-class biomarker assay that will enable faster detection, earlier diagnosis, and better treatment outcomes for the patient.